Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Mol Pharmacol
2008 Jun 01;736:1709-21. doi: 10.1124/mol.108.045591.
Show Gene links
Show Anatomy links
Probing the binding sites and mechanisms of action of two human ether-a-go-go-related gene channel activators, 1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643) and 2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD307243).
Xu X
,
Recanatini M
,
Roberti M
,
Tseng GN
.
???displayArticle.abstract???
We studied the mechanisms and sites of activator actions of 2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid [PD307243 (PD)] and 1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea [NS1643 (NS)] on the human ether-a-go-go-related gene (hERG) channel expressed in oocytes and COS-7 cells. PD and NS affected hERG in a concentration-dependent manner, reaching a maximal increase in current amplitude by 100% and > or = 300% (1-s test pulse to 0 mV), with apparent K(d) values of 3 and 20 microM, respectively. Both drugs slowed hERG inactivation. NS additionally shifted the activation curve in the negative direction, accelerated activation, and slowed deactivation. Kinetic model simulations suggested that the activator effects of PD and NS could be largely accounted for by their effects on the hERG gating kinetics. Both drugs worked from outside the cell membrane but their binding sites seemed to be distinctly different. Perturbing the conformation of outer vestibule/external pore entrance (by cysteine substitution at high-impact positions or cysteine side chain modification at intermediate-impact positions) prevented the activator effect of NS but not that of PD. Furthermore, the peptide toxin BeKm-1, which bound to the outer mouth of the hERG channel, suppressed NS effect but potentiated PD effect. We propose that NS is a "gating-modifier": it binds to the outer vestibule/pore entrance of hERG and increases current amplitudes by promoting channel activation while retarding inactivation. The activator effect of PD was prevented by external quaternary ammonium cations or dofetilide, which approached the hERG selectivity filter from opposite sides of the membrane and depleted K(+) ions in the selectivity filter. We suggest that PD may work as a "pore-modifier" of the hERG channel.
Ahern,
A cation-pi interaction between extracellular TEA and an aromatic residue in potassium channels.
2006, Pubmed
Ahern,
A cation-pi interaction between extracellular TEA and an aromatic residue in potassium channels.
2006,
Pubmed
Brugada,
Sudden death associated with short-QT syndrome linked to mutations in HERG.
2004,
Pubmed
Casis,
Mechanism of action of a novel human ether-a-go-go-related gene channel activator.
2006,
Pubmed
,
Xenbase
Dun,
Allosteric effects of mutations in the extracellular S5-P loop on the gating and ion permeation properties of the hERG potassium channel.
1999,
Pubmed
,
Xenbase
Fan,
Effects of outer mouth mutations on hERG channel function: a comparison with similar mutations in the Shaker channel.
1999,
Pubmed
,
Xenbase
Gandhi,
The orientation and molecular movement of a k(+) channel voltage-sensing domain.
2003,
Pubmed
,
Xenbase
Gordon,
2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD-307243) causes instantaneous current through human ether-a-go-go-related gene potassium channels.
2008,
Pubmed
Hansen,
Activation of human ether-a-go-go-related gene potassium channels by the diphenylurea 1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643).
2006,
Pubmed
,
Xenbase
Jiang,
Dynamic conformational changes of extracellular S5-P linkers in the hERG channel.
2005,
Pubmed
Kamiya,
Molecular determinants of HERG channel block.
2006,
Pubmed
,
Xenbase
Kang,
Discovery of a small molecule activator of the human ether-a-go-go-related gene (HERG) cardiac K+ channel.
2005,
Pubmed
Lainé,
Atomic proximity between S4 segment and pore domain in Shaker potassium channels.
2003,
Pubmed
,
Xenbase
Lenaeus,
Structural basis of TEA blockade in a model potassium channel.
2005,
Pubmed
Liu,
Structural and functional role of the extracellular s5-p linker in the HERG potassium channel.
2002,
Pubmed
,
Xenbase
Long,
Voltage sensor of Kv1.2: structural basis of electromechanical coupling.
2005,
Pubmed
López-Barneo,
Effects of external cations and mutations in the pore region on C-type inactivation of Shaker potassium channels.
1993,
Pubmed
,
Xenbase
Pardo-Lopez,
Mapping the binding site of a human ether-a-go-go-related gene-specific peptide toxin (ErgTx) to the channel's outer vestibule.
2002,
Pubmed
Perry,
Structural basis of action for a human ether-a-go-go-related gene 1 potassium channel activator.
2007,
Pubmed
,
Xenbase
Recanatini,
QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development.
2005,
Pubmed
Roden,
Drug-induced prolongation of the QT interval.
2004,
Pubmed
Sanguinetti,
Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents.
1990,
Pubmed
Sanguinetti,
A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel.
1995,
Pubmed
,
Xenbase
Schreibmayer,
Voltage clamping of Xenopus laevis oocytes utilizing agarose-cushion electrodes.
1994,
Pubmed
,
Xenbase
Smith,
The inward rectification mechanism of the HERG cardiac potassium channel.
1996,
Pubmed
Torres,
Structure of the HERG K+ channel S5P extracellular linker: role of an amphipathic alpha-helix in C-type inactivation.
2003,
Pubmed
Tseng,
I(Kr): the hERG channel.
2001,
Pubmed
Tseng,
Probing the outer mouth structure of the HERG channel with peptide toxin footprinting and molecular modeling.
2007,
Pubmed
,
Xenbase
Wang,
A quantitative analysis of the activation and inactivation kinetics of HERG expressed in Xenopus oocytes.
1997,
Pubmed
,
Xenbase
Yao,
Heterogeneous changes in K currents in rat ventricles three days after myocardial infarction.
1999,
Pubmed
Yeola,
Molecular analysis of a binding site for quinidine in a human cardiac delayed rectifier K+ channel. Role of S6 in antiarrhythmic drug binding.
1996,
Pubmed
Zhang,
BeKm-1 is a HERG-specific toxin that shares the structure with ChTx but the mechanism of action with ErgTx1.
2003,
Pubmed
,
Xenbase
Zhang,
Differential effects of S6 mutations on binding of quinidine and 4-aminopyridine to rat isoform of Kv1.4: common site but different factors in determining blockers' binding affinity.
1998,
Pubmed
,
Xenbase
Zhou,
Novel potent human ether-a-go-go-related gene (hERG) potassium channel enhancers and their in vitro antiarrhythmic activity.
2005,
Pubmed
